PTEN and neoplasm: Of the 17 patients who received trastuzumab plus paclitaxel, those who had PTEN-deficient tumours (− and 1+: IRS<7) had significantly lower complete and partial response rates to trastuzumab therapy than those with PTEN-positive tumors (2+ and 3+ or IRS⩾7; 12.50 vs 88.89%, P=0.00337) (Figure 9).